IL225303A0 - Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid - Google Patents

Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Info

Publication number
IL225303A0
IL225303A0 IL225303A IL22530313A IL225303A0 IL 225303 A0 IL225303 A0 IL 225303A0 IL 225303 A IL225303 A IL 225303A IL 22530313 A IL22530313 A IL 22530313A IL 225303 A0 IL225303 A0 IL 225303A0
Authority
IL
Israel
Prior art keywords
ilmethylbiphenyl
alkoxyimidazole
carboxylic acid
crystalline forms
crystalline
Prior art date
Application number
IL225303A
Other languages
English (en)
Hebrew (he)
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of IL225303A0 publication Critical patent/IL225303A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL225303A 2010-11-10 2013-03-18 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid IL225303A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41201110P 2010-11-10 2010-11-10
PCT/US2011/059895 WO2012064807A1 (en) 2010-11-10 2011-11-09 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Publications (1)

Publication Number Publication Date
IL225303A0 true IL225303A0 (en) 2013-06-27

Family

ID=45003086

Family Applications (1)

Application Number Title Priority Date Filing Date
IL225303A IL225303A0 (en) 2010-11-10 2013-03-18 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Country Status (19)

Country Link
US (3) US8362060B2 (https=)
EP (1) EP2638017B1 (https=)
JP (2) JP2013542258A (https=)
KR (1) KR20130130730A (https=)
CN (1) CN103189362B (https=)
AR (1) AR083828A1 (https=)
AU (1) AU2011326622B2 (https=)
BR (1) BR112013011715A2 (https=)
CA (1) CA2812598A1 (https=)
CO (1) CO6741224A2 (https=)
ES (1) ES2567721T3 (https=)
IL (1) IL225303A0 (https=)
MX (1) MX2013005165A (https=)
NZ (1) NZ609804A (https=)
PH (1) PH12013500945A1 (https=)
RU (1) RU2013126403A (https=)
SG (1) SG189448A1 (https=)
TW (1) TW201300366A (https=)
WO (1) WO2012064807A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法
EP4337638A1 (en) * 2021-05-11 2024-03-20 Astex Pharmaceuticals, Inc. Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
TWI545114B (zh) * 2009-09-29 2016-08-11 施萬生物製藥研發Ｉｐ有限責任公司 製備聯苯基咪唑化合物之方法
US8399501B2 (en) 2010-03-04 2013-03-19 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof

Also Published As

Publication number Publication date
AR083828A1 (es) 2013-03-27
BR112013011715A2 (pt) 2017-10-31
CO6741224A2 (es) 2013-08-30
PH12013500945A1 (en) 2013-07-08
TW201300366A (zh) 2013-01-01
AU2011326622B2 (en) 2014-12-18
HK1187919A1 (zh) 2014-04-17
EP2638017B1 (en) 2016-01-27
RU2013126403A (ru) 2014-12-20
US20120115920A1 (en) 2012-05-10
JP2016028061A (ja) 2016-02-25
MX2013005165A (es) 2013-07-05
US9249105B2 (en) 2016-02-02
US8362060B2 (en) 2013-01-29
US20130267573A1 (en) 2013-10-10
KR20130130730A (ko) 2013-12-02
ES2567721T3 (es) 2016-04-26
JP2013542258A (ja) 2013-11-21
CN103189362A (zh) 2013-07-03
NZ609804A (en) 2015-02-27
CA2812598A1 (en) 2012-05-18
AU2011326622A1 (en) 2013-04-04
US20150133518A1 (en) 2015-05-14
WO2012064807A1 (en) 2012-05-18
US8802709B2 (en) 2014-08-12
CN103189362B (zh) 2015-03-11
EP2638017A1 (en) 2013-09-18
SG189448A1 (en) 2013-05-31

Similar Documents

Publication Publication Date Title
BRPI1013937A2 (pt) compostos de ácido carboxílico
IL236626B (en) Crystal forms of prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
DK2623507T3 (da) Morpholinonukleinsyrederivat
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
HUE040355T2 (hu) Benzilbenzol SGLT2-inhibitor kristályformája
EP2725016A4 (en) HETEROCYCLIC CARBOXYLIC ESTER DERIVATIVE
BR112014029261A2 (pt) compostos de ácido carboxílico
EP2714970A4 (en) Enzyme QUANTIFICATION
IL225867B (en) Coelenterazine substrates
PL2558435T3 (pl) Krystaliczny rombowy mebutynian ingenolu
ZA201300436B (en) Novel calcium salts of compound as anti-inflammatory,immunomodulatory and anti-proliferatory agents
LT3246325T (lt) 2-acilaminotiazolo junginio kristalai
IL229005A0 (en) Pyrazolidin - 3 - one derivatives
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
SI2448945T1 (sl) Kristalinične oblike prasugrelovih soli
EP2548872A4 (en) Cyclopropanecarboxylate DERIVATIVE
ZA201102124B (en) Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
DK2588420T3 (da) Kedelstensfjernelse af oxalater med syresammensætninger
EP2563379A4 (en) SOX9 INHIBITORS
LT3395796T (lt) (3s,3s') 4,4'-disulfandiil-bis-(3-aminobutan-1-sulfonrūgšties) kristalinė trihidrato forma
ZA201206298B (en) Crystalline forms of l-malic acid salt of sunitinib
BR112013002589A2 (pt) valsatana altamente cristalina
EP2593096A4 (en) DICLOFENAC SALT OF TRAMADOL
IL225303A0 (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
IL228486A0 (en) 3-ureidoisoquinolin-8-yl derivatives